Related Experiment Videos
Inositol for respiratory distress syndrome in preterm infants
1Paediatrics (Division of Neonatal Paediatrics), Izaak Walton Killam-Grace Health Centre, 5850/5980 University Avenue, Halifax, Nova Scotia, Canada, B3J 3G9. aahowlet@is.dal.ca
Insights
Inositol supplementation significantly reduced adverse outcomes in preterm infants, including death and bronchopulmonary dysplasia. Further research is needed to confirm these findings.
Area of Science:
- Neonatal Medicine
- Nutritional Science
- Clinical Trials
Background:
- Inositol is an essential nutrient vital for cell growth and surfactant maturation.
- It plays a critical role in fetal and early neonatal development.
Purpose of the Study:
- To evaluate the effectiveness and safety of inositol supplementation in preterm infants with respiratory distress syndrome (RDS).
- To assess its impact on reducing adverse neonatal outcomes.
Main Methods:
- A systematic review of randomized controlled trials (RCTs) was conducted using Medline, Embase, and other databases.
- Studies included preterm infants receiving inositol versus placebo or no intervention.
- Outcomes analyzed included bronchopulmonary dysplasia (BPD), death, retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and sepsis.
Main Results:
- Inositol supplementation significantly reduced the combined outcome of death or BPD (RR 0.56) and death alone (RR 0.48).
- Significant reductions were observed in ROP (RR 0.09) and severe IVH (RR 0.55).
- No increase in sepsis or NEC was noted.
Conclusions:
- Inositol supplementation demonstrates statistically significant and clinically important reductions in short-term adverse neonatal outcomes.
- A large, multi-center RCT is warranted to validate these promising findings.
Background:
Inositol is an essential nutrient required by human cells in culture for growth and survival. Inositol promotes maturation of several components of surfactant and may play a critical role in fetal and early neonatal life.
Objectives:
To assess the effectiveness/safety of supplementary inositol in preterm infants with RDS in reducing adverse neonatal outcomes.
Search Strategy:
Medline, Embase, and Reference Update Databases were searched in August 1997 using key words: inositol and infant-newborn and random allocation or controlled trial or randomized trial (RCT). The reference lists of identified RCTs, personal files and Science Citation Index were searched. Unpublished additional information was obtained from the authors of one RCT published in abstract form.
Selection Criteria:
All randomized controlled trials of inositol supplementation to preterm infants with a control group that received a placebo or no intervention were included. Outcomes of interest were bronchopulmonary dysplasia (BPD), death, BPD or death, retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and sepsis.
Data Collection And Analysis:
Data on neonatal outcomes were abstracted independently by the two researchers and any discrepancy was resolved through consensus. Revman was used for analysis of the data.
Main Results:
Four reports of three RCTs were identified. One report was a duplicate publication. The outcome of death or bronchopulmonary dysplasia was reported in two trials, and was found to be significantly reduced (RR 0.56, 95% CI 0.42, 0.77; RD -0.215, 95% CI -0.323, -0.107). The outcome of death was reported in two trials and was found to be significantly reduced (RR 0.48, 95% CI 0.28, 0.80; RD -0.131, 95% CI -0.218, -0.043). Retinopathy of prematurity, stage 4 or needing therapy, was reported in two trials, and was found to be significantly reduced (RR 0.09, 95% CI 0.01, 0.67; RD -0.078, 95% CI -0.128, -0.027). Intraventricular hemorrhage, grade III-IV, was significantly decreased (RR 0.55, 95% CI 0.32, 0.95; RD -0.090, 95% CI -0.170, -0.010). Neither sepsis nor necrotizing enterocolitis outcomes were increased. When a secondary analysis was done excluding a study published in abstract form, the results differed only in that there was a significant reduction in retinopathy of prematurity, any stage (RR 0.53, 95% CI 0.29, 0.97; RD -0.082, 95% CI -0.159,-0.005).
Reviewer'S Conclusions:
Inositol supplementation results in statistically significant and clinically important reductions in important short-term adverse neonatal outcomes. A multi-center RCT of appropriate size is justified to confirm these findings.